iPD1 CD19 eCAR-T therapy (Marino Biotechnology)

抗CD19分子嵌合抗原受体修饰的自体T淋巴细胞

Report date: 2026/01/08 20:00:10

Base Information

Drug NameiPD1 CD19 eCAR-T therapy (Marino Biotechnology)
Drug Alias NameiPD1 CD19 eCAR T cells创新CD19 eCAR TAnti-CD19 4-1BB-costimulatory chimeric antigen receptor T cell therapy (Marino Biotechnology)创新CD19-eCAR-TMBC19
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsGlioblastomaLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Marino Biotechnology Co LtdChengdu Yinhe Biomedicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSichuan UniversityChengdu Yinhe Biomedicine Co LtdBeijing Marino Biotechnology Co Ltd
Inactive CompaniesPeking University
Active IndicationsLymphoma, B-Cell
Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A